QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RPRX

QT74Royalty Pharma plc
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
52.96
-0.74-1.38%
OverviewShort InterestFilings
RPRXQT74Royalty Pharma plc·NASDAQ
OverviewShort InterestFilings
52.96-1.38%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E28.02EPS (ttm)
1.77
Insider Own18.09%
Shs Outstand575.83M
Perf Week-4.21%
Market Cap23.10BForward P/E9.42EPS next Y5.62Insider Trans-0.14%Shs Float-Perf Month1.05%
Enterprise Value31.47BPEG-EPS next Q1.27Inst Own-Short Float-Perf Quarter16.32%
Income824.59MP/S9.46EPS this Y189.90%Inst Trans-Short Ratio-Perf Half Y37.99%
Sales2.44BP/B3.37EPS next Y9.59%ROA4.18%Short Interest-Perf YTD37.06%
Book/sh17.26P/C8.74EPS next 5Y10.72%ROE12.67%52W High56.50 -6.27%Perf Year53.24%
Cash/sh1.06P/FCF8.70EPS past 3/5Y-ROIC8.43%52W Low34.08 55.40%Perf 3Y-
Dividend Est.0.91 (1.72%)EV/EBITDA18.52Sales past 3/5Y2.06% 2.30%Gross Margin99.95%Volatility2.36% 1.80%Perf 5Y-
Dividend TTM0.91 (1.72%)EV/Sales12.89EPS Y/Y TTM165.45%Oper. Margin67.93%ATR (14)1.35Perf 10Y-
Dividend Ex-DateMay 15, 2026Quick Ratio2.66Sales Y/Y TTM7.82%Profit Margin33.91%RSI (14)45.83Recom2.00
Dividend Gr. 3/5Y5.01% 24.01%Current Ratio2.66EPS Q/Q22.64%SMA20-2.96%Beta0.37Target Price56.67
Payout46.81%Debt/Eq1.30Sales Q/Q11.09%SMA501.82%Rel Volume2.27Prev Close53.70
Employees75LT Debt/Eq0.88EarningsAug 05SMA20022.17%Avg Volume3.78MPrice52.96
IPO DateJun 16, 2020Option/ShortYes / YesEPS/Sales Surpr.7.44% 4.88%Net Debt/EBITDA4.93Volume8,569,186Change-1.38%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-21-26ReiteratedUBSBuy$49 → $57
Apr-10-26ReiteratedMorgan StanleyOverweight$61 → $63
Feb-27-26ReiteratedSeaport Global$50
Feb-12-26ReiteratedMorgan StanleyOverweight$56 → $61
Jan-30-26UpgradeUBSNeutral → Buy$28 → $49
Dec-11-25ReiteratedLeerink Partners$45
Sep-30-25InitiatedGoldman SachsBuy$51 → $42
Jul-10-25ReiteratedMorgan StanleyOverweight$51 → $54
Sep-04-24ReiteratedGoldman SachsBuy$50 → $51
Jun-07-24ReiteratedGoldman SachsBuy$50
Latest News
Jun-09-26
Jun-09-2606:22PM
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,4412,3782,264
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
100
Gross Profit2,4392,3782,264
Selling, General and Administrative Excl. Other622573237
Research and Development4434522
Other Operating Expense-283-206732
Operating Income1,6571,5601,292
Interest Expense337308226
Unusual Expense
———
Non-Operating Income (Expense)-38-72-264
Net Income Before Taxes1,3591,3241,331
Income Taxes
000
Consolidated Net Income827771859
Net Income From Continuing Operations1,3591,3241,331
Net Income827771859
EPS (Recurring)2.462.331.92
EPS (Basic, Before Extraordinaries)2.462.331.92
EPS (Diluted)1.771.801.91
EBITDA1,6981,6361,556
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio29.9221.47—
Price To Sales Ratio9.377.02—
Gross Margin99.92100.00100.00
Operating Margin67.8865.6057.07
Net Margin33.8832.4237.94
Shares Outstanding432432446
Market Capitalization22,87916,692—
Operating Lease Expense
———
Insider Trading Volume
$56.09$51.46$46.83$42.19$37.56● Close Price0.00M4.92M9.83M14.75M19.67MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Coyne Terrance P.EVP & CFOMay 26 '26Sale53.9864,3993,476,1160May 28 12:00 AM
Urist MarshallEVP, Research & InvestmentsMay 20 '26Sale52.7513,684721,83818,197May 21 12:00 AM
Urist MarshallEVP, Research & InvestmentsMay 14 '26Sale53.0613,684726,13731,881May 15 12:00 AM
Norden GregoryDirectorMay 14 '26Sale53.003,045161,385191,803May 15 12:00 AM
Coyne Terrance P.EVP & CFOApr 28 '26Sale49.7834,7911,731,8410Apr 30 12:00 AM
Coyne Terrance P.EVP & CFOApr 01 '26Sale48.3334,7911,681,51232,916Apr 02 12:00 AM
Coyne Terrance P.EVP & CFOMar 23 '26Sale45.5334,7911,583,98943,886Mar 25 12:00 AM
Coyne Terrance P.EVP & CFOMar 02 '26Sale46.7834,7911,627,53445,761Mar 04 12:00 AM
Coyne Terrance P.EVP & CFOFeb 23 '26Sale45.3234,7911,576,60647,636Feb 25 12:00 AM
Coyne Terrance P.EVP & CFOFeb 04 '26Sale43.2920,163872,91222,885Feb 04 12:00 AM
Coyne Terrance P.EVP & CFOFeb 03 '26Sale42.84114,9544,924,99723,972Feb 04 12:00 AM
Coyne Terrance P.EVP & CFOFeb 02 '26Sale42.08108,4244,562,90530,167Feb 04 12:00 AM
Urist MarshallEVP, Research & InvestmentsJan 30 '26Sale41.0920,000821,8100Feb 02 12:00 AM
Urist MarshallEVP, Research & InvestmentsJan 23 '26Sale40.2620,000805,11020,000Jan 26 12:00 AM
Coyne Terrance P.EVP & CFOJan 20 '26Sale39.3569,5822,737,94136,010Jan 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR